加味知柏汤与α受体阻断剂联合治疗慢性前列腺炎的疗效观察  

Observation on Efficacy of Modified Zhibai Decoction Combined with α-retardant in Treatment of Chronic Prostatitis

作　　者：谢建平[1] 

机构地区：[1]深圳市龙岗中心医院中医全科,深圳龙岗514800

出　　处：《中国医院用药评价与分析》2016年第2期169-171,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：探讨加味知柏汤与α受体阻断剂联合治疗慢性前列腺炎的临床疗效。方法:选取深圳市龙岗中心医院2013年2月—2014年10月收治的慢性前列腺炎患者114例,按随机数字表法分成2组各57例。对照组患者给予α受体阻断剂治疗,观察组患者在此基础上联合加味知柏汤治疗。比较2组患者治疗前、后慢性前列腺炎症状评分(NIH-CPSI)的差异,记录最大尿流率、平均尿流率及肿瘤坏死因子α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)变化情况。结果:观察组患者NIH-CPSI评分由治疗前的(23.7±2.7)分降低为治疗后的(13.4±2.2)分,对照组由治疗前的(23.9±2.6)分降低为治疗后的(16.9±2.4)分,均较同组治疗前明显降低,且观察组降低幅度大于对照组,差异有统计学意义(P<0.05)。观察患者最大尿流率由治疗前的(15.8±5.5)V/(ml·s)升高为治疗后的(21.0±2.2)V/(ml·s),对照组由治疗前的(15.9±5.3)V/(ml·s)升高为治疗后的(18.9±2.0)V/(ml·s),均较同组治疗前明显降低,且观察组降低幅度大于对照组,差异有统计学意义(P<0.05)。观察组患者平均尿流率由治疗前的(8.5±3.3)V/(ml·s)升高为治疗后的(12.3±1.9)V/(ml·s),对照组由治疗前的(8.7±3.1)V/(ml·s)升高为治疗后的(10.5±1.7)V/(ml·s),均较同组治疗前明显降低,且观察组降低幅度大于对照组,差异有统计学意义(P<0.05)。观察组患者TNF-α、IL-6、IL-8指标由治疗前的(92.7±33.0)pg/ml、(1.7±0.2)μg/ml、(12.6±2.5)μg/ml降低为治疗后的(63.7±15.1)pg/ml、(1.1±0.2)μg/ml、(7.4±1.0)μg/ml,对照组由治疗前的(92.5±33.1)pg/ml、(1.7±0.3)μg/ml、(12.7±2.3)μg/ml降低为治疗后的(79.9±14.7)pg/ml、(1.5±0.2)μg/ml、(9.3±1.3)μg/ml,均较同组治疗前明显降低,且观察组降低幅度大于对照组,差异有统计学意义(P<0.05)。结论:加味知柏汤与α受体阻断剂联合治疗慢性前列腺炎疗效确切,可有效缓解其炎症反应、改善患者前列腺功能,值�OBJECTIVE： To investigate the clinical efficacy of modified zhibai decoction combined with α-retardant in treatment of chronic prostatitis.METHODS： 114 cases with chronic prostatitis admitted into Shenzhen Longgang Central Hospital from Feb.2013 to Oct.2014 were selected to be divided into two groups via the random number table,with 57 cases in each.The control group were treated with α-retardant therapy,while the observation group additionally received modified zhibai decoction based on the control group.Differences in chronic prostatitis symptom scores（ NIH-CPSI） were compared between two groups before and after treatment,changes of maximal urinary flow rate,average urinary flow rate,TNF-α,IL-6 and IL-8 were recorded.RESULTS： After treatment,NIH-CPSI scores in observation group decreased from（ 23.7 ±2.7） to（ 13.4 ±2.2）,and in control group decreased from（ 23.9 ±2.6） to（ 16.9 ±2.4）,the data in two groups were significantly lower than those before treatment（ P〈0.05）,the decline in observation group was greater than that in control group,with statistically significant difference（ P〈0.05）.The maximal urinary flow rate in observation group increased from（ 15.8 ± 5.5） V /（ ml·s） to（ 21.0 ± 2.2） V /（ ml·s）,and in control group,it decreased from（ 15.9 ± 5.3）V /（ ml·s） to（ 18.9 ±2.0） V /（ ml·s）,the data in two groups were significantly lower than those before treatment（ P〈0.05）,the decline in observation group was greater than that in control group,with statistically significant difference（ P〈0.05）.The average urinary flow rate in observation group increased from（ 8.5 ± 3.3） V /（ ml·s） to（ 12.3 ± 1.9） V /（ ml·s）,and incontrol group,it decreased from（ 8.7 ± 3.1） V /（ ml·s） to（ 10.5 ± 1.7） V /（ ml·s）,the data in two groups were significantly lower than those before treatment（ P〈0.05）,the decline in observation group was greater than that in control group,with statistically signific

关 键 词：加味知柏汤 Α受体阻断剂 慢性前列腺炎 

分 类 号：R944.61[医药卫生—药剂学]